It’s only fair to share… Alixorexton CAS 2648347-56-0 MF C21H30N2O5S MW 422.5 g/mol N-((21S,24S,52R,53S)-6-oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzena-2(1,4)-cyclohexanacyclooctaphane-53-yl)methanesulfonamide N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.02,7.011,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide N-[7,10-cis-(4S,4aR)-17-oxo-1,2,3,4,4a,5,7,8,9,10,16,17-dodecahydro-7,10-ethanopyrido[1,2-d][1,7,4]benzodioxaazacyclotridecin-4-yl]methanesulfonamideorexin-2 receptor agonist, ALKS 2680, Breakthrough Therapy designation, 3BRW4ARU66, TAK 994, firazorexton Alixorexton (formerly ALKS 2680) is an investigational, once-daily, oral, selective orexin 2 receptor (OX2R) agonist being developed by Alkermes for treating narcolepsy and idiopathic hypersomnia. It has shown significant efficacy in Phase 2 trials …